IP Library Granted Patent US 11,730,737
Granted Patent B2
US 11,730,737 · App. 16/886,165 · Granted Aug 22, 2023

Aldose reductase inhibitors and uses thereof

Inventors: Andrew Wasmuth (Brooklyn, NY); Donald W. Landry (New York, NY); Shixian Deng (White Plains, NY); Banavara L. Mylari (East Lyme, CT); Ravichandran Ramasamy (Ardsley, NY); Ann Marie Schmidt (Franklin Lakes, NJ)
Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
A61K31/5025C07D487/04H05K999/99
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,730,737
App. No.
16/886,165
Granted
Aug 22, 2023
Kind
B2
Abstract

The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like.

Claims (30)

1. A method for inhibiting aldose reductase activity in a subject, comprising administering to a subject with neuropathy a therapeutically effective amount of a compound of formula (I)

wherein,

R 1 is H or (C 1 -C 6 )-alkyl;

X 1 is N;

X 2 is CH;

X 3 is CH;

X 4 is N;

Y is C═O, C═S, C═NH, or C═N(C 1 -C 4 )-alkyl;

Z is

A 1 is S;

A 2 is N; and

R 7 through R 10 are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, trifluoroacetyl, (C 1 -C 4 )-alkoxy, (C 1 -C 4 )-alkylthio, (C 1 -C 4 )-alkylsulfinyl, or (C 1 -C 4 )-alkylsulfonyl; or two of R 7 through R 10 taken together are (C 1 -C 4 )-alkylenedioxy;

or a pharmaceutically acceptable salt or solvate thereof.

2. The method of claim 1 , wherein Y is C═O; and R 7 through R 10 are independently hydrogen, halogen, cyano, acyl, haloalkyl, haloalkoxy, haloalkylthio, (C 1 -C 4 )-alkyl, (C 1 -C 4 )-alkoxy, (C 1 -C 4 )-alkylthio, (C 1 -C 4 )-alkylsulfinyl, or (C 1 -C 4 )-alkylsulfonyl.

3. The method of claim 2 , wherein R 7 through R 10 are independently hydrogen, halogen, or haloalkyl.

4. The method of claim 2 , wherein R 7 , R 8 and R 10 are hydrogen; and R 9 is hydrogen, halogen or haloalkyl.

5. The method of claim 1 , wherein R 1 is ethyl or tert-butyl.

6. The method of claim 1 , wherein R 1 is H.

7. The method of claim 1 , wherein the compound of formula (I) is

or a pharmaceutically acceptable salt thereof, wherein R 1 is H or (C 1 -C 6 )-alkyl.

8. The method of claim 7 , wherein R 1 is H.

9. The method of claim 1 , wherein the compound of formula (I) is

or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is H or (C 1 -C 6 )-alkyl.

10. The method of claim 9 , wherein R 1 is H.

11. The method of claim 1 , wherein the compound of formula (I) is

or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is H or (C 1 -C 6 )-alkyl.

12. The method of claim 11 , wherein R 1 is H.

13. The method of claim 1 , wherein the compound of formula (I) is

or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is H or (C 1 -C 6 )-alkyl.

14. The method of claim 13 , wherein R 1 is H.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2020
From: WASMUTH, ANDREW; LANDRY, DONALD W; DENG, SHIXIAN; RAMASAMY, RAVICHANDRAN; SCHMIDT, ANN MARIE; MYLARI, BANAVARA L
To: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Reel/Frame 052869/0669 →
CONFIRMATORY LICENSE Recorded Jun 3, 2020
From: COLUMBIA UNIV NEW YORK MORNINGSIDE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 052819/0805 →
Continuity (7)
Continuation 16598119 · Oct 10, 2019
Continuation 15489834 · Apr 18, 2017
Continuation 14541365 · Nov 14, 2014
Division 13742573 · Jan 16, 2013
Continuation In Part PCTUS2011044038 · Jul 14, 2011
Provisional Application 61365098 · Jul 16, 2010
Related Publication 20200289512A1 · Sep 17, 2020
Cited By (2)
US 12,528,823 US 12,653,825